Calithera Biosciences Inc (CALA)


Stock Price Forecast

March 3, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Calithera Biosciences Inc chart...

About the Company

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.

CEO

Susan Molineaux

Exchange

NASDAQ

Website

www.calithera.com

$18M

Total Revenue

63

Employees

$0M

Market Capitalization

-0.09

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CALA News

Calithera Biosciences, Inc. (CALA)

1d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

MILLENNIUM PHARMACEUTICALS INC's Net Worth

19d ago, source: Benzinga.com

MILLENNIUM PHARMACEUTICALS INC has an estimated net worth of $119 Million. This is based on reported shares across multiple companies, which include Calithera Biosciences, Inc., Day One ...

Pacira BioSciences Inc.

4d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Calithera to Present at the 2021 Jefferies London Healthcare Conference

24d ago, source: ADVFN

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript

17d ago, source: Hosted on MSN

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript February 29, 2024 Pacira BioSciences, Inc. reports earnings inline with expectations. Reported EPS is $0.89 EPS ...

Aptose Biosciences Inc APTO

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Forte Biosciences Inc.

8mon ago, source: CNN

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...

Calithera Biosciences Inc (CALA)

5d ago, source: Investing

Calithera Biosciences, Inc. (NASDAQ:CALA) initiated a phase I/II open-label study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer’s ...

Calithera Biosciences Inc CALA

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Calithera Biosciences Inc (CALA)

20d ago, source: Investing

Calithera Biosciences, Inc. (NASDAQ:CALA) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock ...

CALA Calithera Biosciences, Inc.

13d ago, source: Seeking Alpha

The security has traded for less than one year There is no Wall Street analyst coverage The security is a closed-end fund or a mortgage REIT The security is listed on a non-US exchange The ...

Calithera Biosciences, Inc. (CALA)

26d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...